New Research Highlights Therapeutic Potential of Cannabigerol
A comprehensive new review of scientific research highlights the lesser-known cannabinoid cannabigerol (CBG) as a promising therapeutic agent. The study, published in Molecules, emphasizes CBG’s ability to influence multiple physiological processes, potentially addressing conditions like cancer, inflammation, metabolic disorders, and chronic pain.
The review notes that while research on CBG is still developing, its unique molecular mechanisms set it apart from better-known cannabinoids like delta-9 THC and CBD. CBG interacts not only with the body’s cannabinoid receptors but also with receptors such as α2AR and 5-HT1A, which play roles in neuroprotection and mood regulation.
Potential Therapeutic Benefits
The study, authored by a 10-person team from institutions in China and the United States, identifies a range of possible therapeutic applications for CBG, including:
- Neuroprotection: CBG could help treat neurodegenerative diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis by improving motor function and reducing brain stress markers.
- Pain Management: Evidence suggests CBG may reduce pain sensitivity by interfering with pain signal transmission.
- Anti-Inflammatory and Antibacterial Effects: CBG shows potential in fighting infections and reducing inflammation.
- Cancer Treatment: The cannabinoid’s mechanisms may inhibit tumor growth, though further research is needed.
While some users report better sleep with CBG, the review notes clinical confirmation is still pending.
Unique Mechanisms and the Need for Further Research
Unlike other cannabinoids, CBG exhibits distinct interactions with the nervous system, which researchers believe could unlock new treatment avenues. The review calls for more studies focusing on CBG alone to fully understand its therapeutic mechanisms, especially in the context of neuroprotection and pain relief.
